Loading...
•
Jun 30, 2022
Regulus Therapeutics Q2 2022 Earnings Report
Regulus Therapeutics reported financial results for the second quarter ended June 30, 2022, and provided a corporate update.
Key Takeaways
Regulus Therapeutics reported a net loss of $7.3 million, or $0.50 per share, and had $47.5 million in cash, cash equivalents and marketable securities as of June 30, 2022. The company also announced the dosing of the first subject in its Phase 1 SAD study of RGLS8429 for the treatment of ADPKD and the appointment of Amin Kamel, Ph.D., as Vice President, DMPK.
First subject dosed in Phase 1 SAD study of RGLS8429 for ADPKD treatment.
RGLS8429 granted Orphan Drug Designation from the FDA.
Amin Kamel, Ph.D., appointed as Vice President, Drug Metabolism and Pharmacokinetics (DMPK).
Cash, cash equivalents and marketable securities totaled $47.5 million as of June 30, 2022.